Intestinal pathology and gut microbiota alterations in a methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Patients with Parkinson's disease (PD) often have non-motor symptoms related to gastrointestinal (GI) dysfunction, such as constipation and delayed gastric emptying, which manifest prior to the motor symptoms of PD. Increasing evidence indicates that changes in the composition of the gut microbiota may be related to the pathogenesis of PD. However, it is unclear how GI dysfunction occurs and how gut microbial dysbiosis is caused. We investigated whether a neurotoxin model of PD induced by chronic low doses of MPTP is capable of reproducing the clinical intestinal pathology of PD, as well as whether gut microbial dysbiosis accompanies this pathology. C57BL/6 male mice were administered 18 mg/kg MPTP twice per week for 5 weeks via intraperitoneal injection. GI function was assessed by measuring the 1-h stool frequency and fecal water content; motor function was assessed by pole tests; and tyrosine hydroxylase and alpha-synuclein expression were analyzed. Furthermore, the inflammation, intestinal barrier and composition of the gut microbiota were measured. We found that MPTP caused GI dysfunction and intestinal pathology prior to motor dysfunction. The composition of the gut microbiota was changed; in particular, the change in the abundance of Lachnospiraceae, Erysipelotrichaceae, Prevotellaceae, Clostridiales, Erysipelotrichales and Proteobacteria was significant. These results indicate that a chronic low-dose MPTP model can be used to evaluate the progression of intestinal pat…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, Lai et al. 51 discovered that the gut microbiota of the MPTP-induced model was significantly altered, especially in the Lachnospiraceae, Erysipelotrichaceae, Prevotellaceae, Clostridiales, Erysipelotrichales and Proteobacteria.51”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [51]
In the citing paper
“Concerning PD, dysbiosis followed by GI symptoms and gut discomfort far precedes the onset of motor dysfunctions and it is linked to neuroinflammation, as well as to alterations in dopamine, serotonin, and kynurenine metabolism through the gut-brain axis [40,41,42,43,44,45,46]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [43]
Citations
Cites
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Gut–brain axis: How the microbiome influences anxiety and depression
Foster, J. A., & McVey Neufeld, K.-A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.01.005 · Cited by 2,460
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
Microglia-specific localisation of a novel calcium binding protein, Iba1
Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., & Kohsaka, S. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00040-0 · Cited by 1,476
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Martin, C. R., Osadchiy, V., Kalani, A., & Mayer, E. A. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.04.003 · Cited by 1,284
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
Xu, N., Tan, G., Wang, H., & Gai, X. (2016) · European Journal of Soil Biology · doi:10.1016/j.ejsobi.2016.02.004 · Cited by 1,180
Unger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159
Biddle, A., Stewart, L., Blanchard, J., & Leschine, S. (2013) · Diversity · doi:10.3390/d5030627 · Cited by 1,025
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
Gastrointestinal dysfunction in Parkinson's disease
Pfeiffer, R. F. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00307-7 · Cited by 925
Hill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Sun, M.-F., Zhu, Y.-L., Zhou, Z.-L., Jia, X.-B., Xu, Y.-D., Yang, Q., Cui, C., & Shen, Y.-Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.005 · Cited by 736
Insights into the Role of Erysipelotrichaceae in the Human Host
Kaakoush, N. O. (2015) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2015.00084 · Cited by 721
Neuroinflammation in Parkinson's disease
Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657
Neuropathology of Parkinson disease
Dickson, D. W. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.033 · Cited by 623
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598
Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder
Vuong, H. E., & Hsiao, E. Y. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.08.024 · Cited by 595
Carvalho, F. A., Koren, O., Goodrich, J. K., Johansson, M. E. V., Nalbantoglu, I., Aitken, J. D., Su, Y., Chassaing, B., Walters, W. A., González, A., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.07.004 · Cited by 548
Antharam, V. C., Li, E. C., Ishmael, A., Sharma, A., Mai, V., Rand, K. H., & Wang, G. P. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00845-13 · Cited by 485
Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., & Gross, C. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06853.2001 · Cited by 483
Li, W., Wu, X., Hu, X., Wang, T., Liang, S., Duan, Y., Jin, F., & Qin, B. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9001-4 · Cited by 406
Intracellular signaling in M‐CSF‐induced microglia activation: Role of Iba1
Imai, Y., & Kohsaka, S. (2002) · Glia · doi:10.1002/glia.10149 · Cited by 359
Role of cytokines in inflammatory process in Parkinson’s disease
Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331
Structural alterations of the intestinal epithelial barrier in Parkinson’s disease
Clairembault, T., Leclair-Visonneau, L., Coron, E., Bourreille, A., Le Dily, S., Vavasseur, F., Heymann, M.-F., Neunlist, M., & Derkinderen, P. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0196-0 · Cited by 291
Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology
Drolet, R. E., Cannon, J. R., Montero, L., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.017 · Cited by 257
ANDERSON, G., NOORIAN, A., TAYLOR, G., ANITHA, M., BERNHARD, D., SRINIVASAN, S., & GREENE, J. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.010 · Cited by 238
Mancuso, C., & Santangelo, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.009 · Cited by 232
Phillips, R. J., Walter, G. C., Wilder, S. L., Baronowsky, E. A., & Powley, T. L. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.02.074 · Cited by 188
Ling, Z., Jin, C., Xie, T., Cheng, Y., Li, L., & Wu, N. (2016) · Scientific Reports · doi:10.1038/srep30673 · Cited by 185
Yang, X., Qian, Y., Xu, S., Song, Y., & Xiao, Q. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00441 · Cited by 173
MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut
Natale, G., Kastsiushenka, O., Fulceri, F., Ruggieri, S. A., Paparelli, A., & Fornai, F. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.076 · Cited by 101
Gargari, G., Taverniti, V., Gardana, C., Cremon, C., Canducci, F., Pagano, I., Barbaro, M. R., Bellacosa, L., Castellazzi, A. M., Valsecchi, C., et al. (2018) · Environmental Microbiology · doi:10.1111/1462-2920.14271 · Cited by 100
Chronic and progressive Parkinson's disease MPTP model in adult and aged mice
Muñoz‐Manchado, A. B., Villadiego, J., Romo‐Madero, S., Suárez‐Luna, N., Bermejo‐Navas, A., Rodríguez‐Gómez, J. A., Garrido‐Gil, P., Labandeira‐García, J. L., Echevarría, M., López‐Barneo, J., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13409 · Cited by 92
Toxin-Induced and Genetic Animal Models of Parkinson's Disease
Hisahara, S., & Shimohama, S. (2011) · Parkinson's Disease · doi:10.4061/2011/951709 · Cited by 91
Côté, M., Bourque, M., Poirier, A.-A., Aubé, B., Morissette, M., Di Paolo, T., & Soulet, D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.05.017 · Cited by 55
The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity
Côté, M., Drouin‐Ouellet, J., Cicchetti, F., & Soulet, D. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.02.017 · Cited by 51
Perry, T. L., Yong, V. W., Jones, K. L., Wall, R. A., Clavier, R. M., Foulks, J. G., & Wright, J. M. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90074-6 · Cited by 50
Cell death induced by MPTP, a substrate for monoamine oxidase B
Nicotra, A., & Parvez, S. H. (2000) · Toxicology · doi:10.1016/s0300-483x(00)00311-5 · Cited by 49
Poirier, A.-A., Côté, M., Bourque, M., Morissette, M., Paolo, T. D., & Soulet, D. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.004 · Cited by 43
The power in numbers: Gut microbiota in Parkinson's disease
Vizcarra, J. A., Wilson, H., & Espay, A. J. (2014) · Movement Disorders · doi:10.1002/mds.26116 · Cited by 40
Restoration of intestinal function in an MPTP model of Parkinson’s Disease
Ellett, L. J., Hung, L. W., Munckton, R., Sherratt, N. A., Culvenor, J., Grubman, A., Furness, J. B., White, A. R., Finkelstein, D. I., Barnham, K. J., et al. (2016) · Scientific Reports · doi:10.1038/srep30269 · Cited by 37
The brain to gut pathway: a possible route of prion transmission
Lawson, V. A., Furness, J. B., Klemm, H. M., Pontell, L., Chan, E., Hill, A. F., & Chiocchetti, R. (2010) · Gut · doi:10.1136/gut.2010.222620 · Cited by 33
Nonmotor symptoms in Parkinson’s disease
Hussl, A., Seppi, K., & Poewe, W. H. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.53 · Cited by 29
Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease
Liang, X., Wen-ting, Z., Xu, Y., Chong-Fa, L., Lu, Z., Jin-jun, R., & Wang, W. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.011 · Cited by 15
Cited by
Chen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917
Zhao, Z., Ning, J., Bao, X.-Q., Shang, M., Ma, J., Li, G., & Zhang, D. (2021) · Microbiome · doi:10.1186/s40168-021-01107-9 · Cited by 616
“Later at week 6, alpha diversity decreased in the rotenone group, which is also witnessed in some other PD models [38, 59].”
ResultChen, Z., Li, G., & Liu, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104700 · Cited by 363
Suganya, K., & Koo, B.-S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207551 · Cited by 368
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Metadata
- Authors
- Lai, F., Jiang, R., Xie, W., Liu, X., Tang, Y., Xiao, H., Gao, J., Jia, Y., & Bai, Q.
- Affiliations
- Chongqing Medical University (CN)
- Corresponding author
- Bai, Qunhua
- Venue
- Neurochemical Research
- Published
- 2018-08-31
- Volume
- 43
- Issue
- 10
- Pages
- 1986-1999
- ISSN
- 0364-3190 (ISSN-L)
- 1573-6903
- OpenAlex
- W2888863770
- Semantic Scholar
- 7d176d8628c515d6563081ca7a92a83e24bc11d6
- Cited by
- 169
- References
- 48
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 24 · 2023: 26 · 2022: 36 · 2021: 27 · 2020: 20 · 2019: 8 · 2018: 1
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neurochemical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chongqing Yuzhong Nature Science Foundation of China (20160121)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, MPTP mouse model, gut dysbiosis, intestinal pathology, gastrointestinal dysfunction, constipation, alpha-synuclein, tyrosine hydroxylase, intestinal barrier, intestinal inflammation, Lachnospiraceae, Erysipelotrichaceae, Prevotellaceae, Clostridiales, Proteobacteria, non-motor symptoms
- MeSH terms
- Gastrointestinal Microbiome, Animals, Disease Models, Animal, Gastrointestinal Diseases, Inflammation, Male, Mice, Inbred C57BL, Parkinson Disease, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Enteric Nervous System, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.